Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

• Status: NOT_YET_RECRUITING
• Trial end date: 2036-07-01

Summary

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

• Phase: PHASE2

Details

• Lead Sponsor: University of Chicago
• Treatments: Ado-Trastuzumab Emtansine; Docetaxel; Goserelin; Letrozole; pertuzumab; Tamoxifen